falsefalse

Polycythemia Vera and Myelofibrosis: Current and Future Standards of Care - Episode 8

Myelofibrosis: FDA Approved Treatment Options and Updates from ASH 2023

, , , ,

Overview of the current FDA approved treatment options for the management of myelofibrosis as well as reviewing recent updates from ASH 2023 on the SIMPLIFY and PERSIST trials.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Diagnosing Polycythemia Vera (PV)
    EP. 2: Polycythemia Vera: Assessing Risk and Genetic Testing
    EP. 3: Polycythemia Vera: Treatment Goals and Options
    EP. 4: REVEAL Study: Clinical Implications
    EP. 5: Polycythemia Vera: Choosing the Right Treatment
    EP. 6: MAJIC-PV: Clinical Implications in PV
    EP. 7: Role of Transplant in Myelofibrosis
    Now Viewing
    EP. 8: Myelofibrosis: FDA Approved Treatment Options and Updates from ASH 2023
    EP. 9: Treating Patients with Myelofibrosis and Anemia
    EP. 10: Monitoring Patients on Myelofibrosis Treatment
    EP. 11: Future of PV: Unmet Needs
    EP. 12: Combination Therapies for MF Management
    EP. 13: Future of MF

    Related Content:

    Polycythemia Vera and Myelofibrosis: Current and Future Standards of CareMyeloproliferative NeoplasmsHematologic Oncology
    Inflation Reduction Act Leads to Seesaw Effect Between Oncologic Drug Savings and Development
    FDA Lifts Clinical Hold on Tabelecleucel Trial for EBV+ Post-Transplant Lymphoproliferative Disease
    Dr Gerds on the Development of Anemia in Low-Risk Myelofibrosis
    x